Subscribe for full access
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2.33
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 10.38
Low: 0.75
High: 20
Total Analysts: 6
Company Profile
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is developing vurolenatide, a proprietary long-acting GLP-1 agonist in Phase 3 development for short bowel syndrome as well as near clinical-stage assets including NM-136 for obesity disorders. The long-acting linker technology is designed specifically to address the gastric effects in SBS patients by slowing digestive transit time. Vurolenatide uses proprietary XTEN technology to extend the half-life of exenatide, potentially allowing for every other week dosing (Q2W). NM-136 is a long-acting, highly specific, humanized anti-GIP monoclonal antibody.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
